To verify whether miR-9 enhances NSCLC cell cisplatin sensitivity by regulating eIF5A2 expression, we silenced eIF5A2 and transfected the cells with miR-9 mimic or inhibitor before examining the cell viability via CCK-8. Here, EIF5A2 is linked to non-small cell lung carcinoma.